A discussion on the SIGNAL Trial: anti-semaphorin 4D Immunotherapy in Huntington's disease
Dates and Times
Start: 9/13/2019 8:00 AM
End: 9/13/2019 9:00 AM
- To review the diagnosis and treatment of Huntington's disease
- To provide an update on the status of a large ongoing multicenter clinical trial of a novel therapy for Huntington's disease (the SIGNAL trial)
HSC level 3, lecture hall 6
Stony Brook Medicine
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.